St. Michael's Hospital ·
Area of research
Endocrinology, Diabetes and Metabolism · Surgery
Research interest
Research interests include Diabetes Treatment and Management, Lipoproteins and Cardiovascular Health, Diabetes, Cardiovascular Risks, and Lipoproteins, and Diabetes Management and Research.
Intermittent fasting strategies and their effects on body weight and other cardiometabolic risk factors: systematic review and network meta-analysis of randomised clinical trials
Galectin-3 and Kidney Function in Type 2 Diabetes Treated with Dapagliflozin: Analysis from DECLARE-TIMI 58
DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases
The Diabetes Technology Society Error Grid and Trend Accuracy Matrix for Glucose Monitors
Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events
Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes
Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial
Natriuretic Peptides, Body Mass Index and Heart Failure Risk: Pooled Analyses of SAVOR-TIMI 53, DECLARE-TIMI 58 and CAMELLIA-TIMI 61
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk
A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings
Association of Low- and No-Calorie Sweetened Beverages as a Replacement for Sugar-Sweetened Beverages With Body Weight and Cardiometabolic Risk
Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: A post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials
Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial
Relation of Change or Substitution of Low- and No-Calorie Sweetened Beverages With Cardiometabolic Outcomes: A Systematic Review and Meta-analysis of Prospective Cohort Studies
Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58
Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials
Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial
Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements
Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial
Epidemiology of the diabetes-cardio-renal spectrum: a cross-sectional report of 1.4 million adults
Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58
Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes
Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58
2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults
The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58
Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure
Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE–TIMI 58 trial
From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes
Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes
A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes